The decreased expression of Fads1 is associated with the increased total lipid content in the liver, as well as obesity, MAFLD, and other metabolic disorders (Araya et al., 2010; Wang et al., 2015; Murakami et al., 2008). Here, FADS1 is linked to metabolic disease.